Cataba­sis Phar­ma­ceu­ti­cals snaps up HAE an­ti­body in buy­out; Glad­stone, UCSF sci­en­tist spear­head launch of neu­ro re­search cen­ter

A few months af­ter fi­nal­ly ad­mit­ting de­feat on their failed Duchenne MD pro­gram, Cataba­sis Phar­ma­ceu­ti­cals is head­ing in a new di­rec­tion with the pur­chase of Quel­lis Bio­sciences and their lead an­ti­body for hered­i­tary an­gioede­ma.

Cataba­sis shared the news on Fri­day that they’re buy­ing out Quel­lis, a rare dis­ease-fo­cused biotech that was un­veiled over a year ago by Chris Garabe­di­an and Per­cep­tive Ad­vi­sors’ PXV Fund. With it, Cataba­sis is snap­ping up QLS-215, a mon­o­clon­al an­ti­body in­hibitor of plas­ma kallikrein. The can­di­date is cur­rent­ly in pre­clin­i­cal de­vel­op­ment — but won’t be for long, ac­cord­ing to Cataba­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.